News

25^th October 2022: Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the extraordinary pace and productivity of Alnylam’s RNAi therapeutics pipeline.

Using Paradigm4’s cloud-based scientific analytics platform and data from the UK Biobank, Alnylam has identified several novel therapeutic targets, including its latest discovery of the association of the gene INHBE with protection against abdominal obesity and metabolic syndrome – a condition impacting more than 20% of adults worldwide. These findings support the potential of INHBE as a novel therapeutic target to be investigated for the treatment of cardiometabolic disease. The ability to mimic gene loss-of-function using its RNAi platform in conjunction with large-scale human genetic data is fundamental to Alnylam’s continued productivity in Phase 3 trials.

Dr. Paul Nioi, VP, Discovery and Translational Research at Alnylam Pharmaceuticals commented on the significance of the partnership with Paradigm4:

‘We have uncovered insights that, without this system, would not have been possible. Paradigm4’s platform has become instrumental to our target discovery efforts.’

Fundamental to Paradigm4’s REVEAL platform is a unique technology stack for working with high dimension, content diverse, genotypic and longitudinal phenotypic data at human population scales, soon to be counted in millions. Scientific data is integrated with an elastic computing engine for no-code to low code exploration, comprehensive analytics, and machine-learning that delivers ease-of-use, automated scalability, and unmatched cloud-centric economics.

By pairing Paradigm4’s unique technology with a platform for rationally-designed, sequence-based precision medicines, Alnylam can go from target discovery to a Phase 1 clinical trial in as little as 18 months. The compute-speed and cost-efficiency of the REVEAL platform gives Alnylam the freedom to explore the genetics underlying many human diseases, both rare and common. Using Paradigm4’s platform, the team at Alnylam is able to run many large-scale in-silico experiments, such as Genome Wide Association Studies (GWAS), to identify disease-relevant targets amenable to Alnylam’s siRNA-based platform. Paradigm4’s REVEAL enables these studies through its Biobank API, which greatly simplifies the generation and analysis of custom data subsets with a wide variety of genetic analysis packages. Using REVEAL, Alnylam scientists can systematically calculate single-variant and gene-level tests on a dynamic burst cluster that scales to 200 or more spot workers in a time- and cost-efficient manner.

Greg Hinkle, VP of Research Informatics at Alnylam Pharmaceuticals, commented as well:

“The scale and pace in growth of human genetics data is an extraordinary semantic and computational challenge. We continue to marvel at Paradigm4’s ability to manage the ever-growing complexities in the day-to-day work of incorporating new genetics tool sets and the constant expansion of novel, diverse phenotypic data. We endeavour to be the leaders in developing genetically validated RNAi therapeutics and the REVEAL platform has made this possible.”

Dr. Paul Nioi, V.P., Discovery and Translational Research at Alnylam Pharmaceuticals continued:

‘Alternative approaches are just not equipped to be able to go into the data in the way that we can.Paradigm4 really has been the enabler of much of what we’ve accomplished, and it will continue to be a critical resource for us going forward.’

About Paradigm4

Paradigm4 transforms scalable translational understanding from whole body to cells with its REVEAL Integrative Analytics Platform. REVEAL’s novel scientific data store, integrated with our optimal elastic computing engine for no-code to low code exploration, analytics, and machine-learning delivers the trifecta of ease-of-use, automated scalability, and unmatched cloud economics. REVEAL streamlines interactive, collaborative, and reproducible science, propelling drug development and precision medicine at global pharmas and biotechs. For more information, visit paradigm4.com and email us at lifesciences@paradigm4.com

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding 20 years ago, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), AMVUTTRA® (vutrisiran) and Leqvio® (inclisiran) being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam, on LinkedIn, or on Instagram.

Media contact

Hannah Steele
The Scott Partnership
+44 (0)1477 539539

paradigm4@scottpr.com

Paradigm4 has launched the Precision Cell Atlas^TM as an integral component of its REVEALTM: SingleCell app. The Precision Cell Atlas enables scientists to create a custom cell atlas by selectively combining an unlimited number of samples from multiple datasets for specific research objectives and explicitly saving them for collaboration, reuse, and regulatory filings.

REVEAL: SingleCell, together with the Precision Cell Atlas capability, includes industry standard statistical tools to assess the sample-to-sample variation in gene vectors while retaining the provenance from the original project metadata for each sample. Metadata is tracked in the immutable log files recorded with REVEAL: SingleCell.

With its initial launch in 2020, REVEAL: SingleCell was developed to offer biopharmaceutical computational biologists the ability to break through the data wrangling and programming challenges associated with the analysis of large-scale, single-cell datasets. The app enables users to navigate multimodal disease biology, scale to handle more samples from patients with more cells, more features, and diverse data types. Users can readily assess key biological hypotheses for target evaluation, disease progression, and precision medicine applications.

Paradigm4’s REVEAL suite of use case-specific applications were built to transform scalable translational understanding from whole body to organelle. Other apps developed by Paradigm4 include REVEALTM: Proteomics and REVEALTM: Biobank. The apps are powered by Paradigm4’s unique technology stack, designed for scalable and interactive exploration, analytics, and machine learning on heterogeneous and highly dimensional scientific data sets.

Zachary Pitluk, Ph.D., VP of Life Sciences and Healthcare at Paradigm4, commented: “Since its launch, REVEAL: SingleCell has been embraced by the single cell analysis community, with as many as 80 million cells in play in some installations. Current customer installations are supporting thousands of queries per day with the present implementation. Importantly, the addition of the Precision Cell Atlas functionality should increase the supportable queries and drive projects forward at a much faster rate than is currently available.”

For more information about Paradigm4, visit https://www.paradigm4.com/.

BOSTON — Paradigm4 has today unveiled REVEAL™: Proteomics, the newest use case specific app powered by the Paradigm4 FLASH™ high-performance bioinformatics platform.

REVEAL: Proteomics unlocks the power of advanced mass spec proteomics by simplifying cross sample and cross study searching for protein isoforms as potential biomarkers for drug response or disease progression. REVEAL: Proteomics directly addresses the time-consuming data science challenge of preparing individual data sets for analysis, manual curation of identities, and the limitations of how many samples can be compared. The REVEAL: Proteomics app allows hypothesis testing in seconds across an unlimited number of studies. The new application aims to streamline disease research with integrated protein-gene mappings between HUGO and ENSEMBL ontologies, enabling analysis in an ad hoc manner without connecting to external websites.

REVEAL: Proteomics is built on top of Paradigm4’s FLASH next generation analytics platform, designed for rapid data slicing to enable scientific data modelling, storage, and population-scale computation. The efficient storage architecture of FLASH and Paradigm4’s focus on optimal execution speed means the total cost of ownership (TCO) is predicable, and significantly lower than other bioinformatics ecosystem approaches. REVEAL: Proteomics ensures that data and analysis are shareable with colleagues globally through Paradigm4’s high-throughput elastic file system, flexFS.

Paradigm4’s REVEAL apps are a suite of use case-specific applications that power discovery from population-scale to small studies. Other apps developed by Paradigm4 include REVEAL: Single Cell, which enables users to build a multidimensional understanding of disease biology, scale to handle more samples from patients, with more cells, and readily assess key biological hypotheses for target evaluation, disease progression, and precision medicine.

Zachary Pitluk, Ph.D., VP of Life Sciences and Healthcare at Paradigm4, commented: “REVEAL: Proteomics makes the use of protein isoforms practical for understanding diseases and drug response. It allows the testing of hypotheses against your entire collection of studies and the broad range of conditions and treatments. REVEAL: Proteomics truly enables protein isoform biomarker discovery and use.”

“Our high-performance computing platform empowers data scientists to perform deeper analysis in an ad hoc manner. The REVEAL: Proteomics app is the latest addition to our suite of REVEAL applications, as we look to make it easier for researchers to search and access their proteomic data and transform the discovery of new biomarkers.”

For more information about Paradigm4, please contact lifesciences@paradigm4.com or visit https://www.paradigm4.com/.

About Paradigm4

Paradigm4 translates bioinformatics data into real-world discoveries. Its high-performance data management and scalable computing solutions are being used by pharma and biotech companies to uncover new insights in a way that is both interactive and cost-effective. The integrative platform allows users to interrogate and explore data for discovery, as well as facilitating ad hoc analysis. With the REVEAL suite of extensible cloud-driven apps, users can power massively scalable analytics and machine-learning on multimodal data to propel their drug discovery.

 

Paradigm4, an integrated scientific data analytics company, has launched flexFS, its elastic cloud file system for flexible and more resource-efficient data storage and scalable computing.

Paradigm4 has launched its REVEAL™: Multi-Omics app, allowing researchers to undertake advanced, cross-study analyses and enable quick searches for genes and proteins across all integrated public reference and proprietary datasets.

 More sensitive technology spurs proteomic and metabolomic biomarker identification, clinical use. (Complete article on page 21)

12 JANUARY 2021: Paradigm4, specialist in scientific data management and scalable computation, has signed an agreement with 54gene, a health technology company deriving insights from the world’s most diverse populations to solve some of healthcare’s biggest challenges. The agreement will allow 54gene to use Paradigm4’s REVEAL^TM Biobank app to explore, characterize and query the growing repository of data that constitutes 54gene’s pioneering African Health Information Ecosystem, which is a highly curated, unique data source of clinical, phenotypic and genetic information from which insights can be generated that lead to new treatments and diagnostics.

Africa contains more genetic diversity than any other continent, however, fewer than 3% of the genomes analyzed to date have come from Africans¹. As a result, information that could prove beneficial to the improvement of healthcare for all populations across the world, may be missed. 54gene is working to change this by collaborating with researchers on the African continent to include the world’s most genetically diverse population in global genomics research that can be used to power drug discoveries and derive therapeutic insights in healthcare for the benefit of all populations.

The REVEAL^TM Biobank app that 54gene will use is built on top of Paradigm4’s novel computational database engine, SciDB^TM, which is purpose-built to handle large-scale heterogeneous scientific data. The REVEAL^TM Biobank provides researchers with an easy-to-use way to access their high-resolution, multi-dimensional and multi-attribute data. Users can fluidly combine diverse data sources like genotypic, phenotypic, biomedical imaging, and health records for cross-validation and enrichment. The app is also optimized for scalable advanced analytics and machine learning.

Marilyn Matz, co-founder and CEO of Paradigm4, commented:

“We’re delighted to be partnering with 54gene on this exceptionally important project to create an inclusive bank of genetic data for African people that has the potential to change the way pharma companies develop personalized medicine. Our REVEAL^TM Biobank app accelerates integrative, multimodal, longitudinal, population-scale data science exploration and discovery, which will provide 54gene with an unrivalled ability to interrogate its extensive and diverse datasets.”

Delali Attiogbe Attipoe, Chief Operating Officer at 54gene, commented:

“We discovered Paradigm4 via its work with the UK Biobank and were impressed by REVEAL^TM Biobank’s cohort selector tool and R API with complex computing capacity. This will help us conduct detailed analysis of a variety of genotypic and phenotypic data within our African Health Information Ecosystem. Working with Paradigm4 and its intuitive app will allow us to uncover genetic connections and associations that will help support the development of therapeutics for a variety of diseases. By better understanding the genetic drivers of disease, we can ensure that African people and the global community benefit from cutting-edge medical innovation developed from the insights we have generated.”

For more information about Paradigm4, email lifesciences@paradigm4.com

 

Neil Versel

Zach Pitluk, Ph.D.

Interview with Marilyn Matz, CEO and Co-founder at Paradigm4, and 2020 NACD Directorship 100™ honoree, and her colleague Dr. Zachary Pitluk, VP of Life Sciences and Health Care at Paradigm4.

Founded by renowned database researcher, Turing Award laureate MIT Professor Michael Stonebraker, Paradigm4 is not just any data analytics company in the Life Sciences. The organization is built on the decades of pioneering research in database design and possesses unique technological know-how in scientific data management and scalable computation.

READ FULL ARTICLE